Publications by authors named "Ryan M Kendra"
Article Synopsis
- Rituximab, a B-cell depleting drug, is used to treat autoimmune myositis, and the study aims to understand its effects beyond just B-cell depletion.
- Researchers analyzed muscle biopsies from myositis patients before and after rituximab treatment, finding significant differences in gene expression between responders and non-responders to the therapy.
- The study concluded that rituximab may improve myositis symptoms through mechanisms involving increased ESR1 signaling, rather than solely targeting B cells, as evidenced by its interaction with alternative targets on muscle cells.
Background: AAV-based gene therapy is an attractive approach to treat Duchenne muscular dystrophy (DMD) patients. Although the long-term consequences of a gene therapy approach for DMD are unknown, there is evidence in both DMD patients and animal models that dystrophin replacement by gene therapy leads to an anti-dystrophin immune response that is likely to limit the long-term use of these therapeutic strategies.
Objective: Our objective is to test whether the anti-dystrophin immune response is affected by immunomodulatory drugs in mdx mice after rAAV gene therapy.